A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
Trial details
- Registry ID
- NCT04508621
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Low dose cyclobenzaprine sublingual tablets; Tonmya(R); cyclobenzaprine; cyclobenzaprine HCI; cyclobenzaprine HCl
| No regulatory events match this view.This does not mean no FDA events have occurred. |